170 related articles for article (PubMed ID: 38010880)
1. From complement to complosome in non-alcoholic fatty liver disease: When location matters.
Nguyen VD; Hughes TR; Zhou Y
Liver Int; 2024 Feb; 44(2):316-329. PubMed ID: 38010880
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
3. Complosome - the intracellular complement system.
West EE; Kemper C
Nat Rev Nephrol; 2023 Jul; 19(7):426-439. PubMed ID: 37055581
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease.
Lakhani HV; Sharma D; Dodrill MW; Nawab A; Sharma N; Cottrill CL; Shapiro JI; Sodhi K
Int J Med Sci; 2018; 15(14):1591-1599. PubMed ID: 30588181
[TBL] [Abstract][Full Text] [Related]
5. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.
Fernández-Tussy P; Fernández-Ramos D; Lopitz-Otsoa F; Simón J; Barbier-Torres L; Gomez-Santos B; Nuñez-Garcia M; Azkargorta M; Gutiérrez-de Juan V; Serrano-Macia M; Rodríguez-Agudo R; Iruzubieta P; Anguita J; Castro RE; Champagne D; Rincón M; Elortza F; Arslanow A; Krawczyk M; Lammert F; Kirchmeyer M; Behrmann I; Crespo J; Lu SC; Mato JM; Varela-Rey M; Aspichueta P; Delgado TC; Martínez-Chantar ML
Mol Metab; 2019 Nov; 29():40-54. PubMed ID: 31668391
[TBL] [Abstract][Full Text] [Related]
6. Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis.
Peters KM; Wilson RB; Borradaile NM
Curr Opin Lipidol; 2018 Oct; 29(5):417-422. PubMed ID: 30015675
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems.
Soto-Gutierrez A; Gough A; Vernetti LA; Taylor DL; Monga SP
Exp Biol Med (Maywood); 2017 Oct; 242(16):1605-1616. PubMed ID: 28467181
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
[TBL] [Abstract][Full Text] [Related]
9. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Zhang X; Ji X; Wang Q; Li JZ
Protein Cell; 2018 Feb; 9(2):164-177. PubMed ID: 28643267
[TBL] [Abstract][Full Text] [Related]
10. The role of the immune system in the pathogenesis of NAFLD and potential therapeutic impacts of mesenchymal stem cell-derived extracellular vesicles.
Moayedfard Z; Sani F; Alizadeh A; Bagheri Lankarani K; Zarei M; Azarpira N
Stem Cell Res Ther; 2022 Jun; 13(1):242. PubMed ID: 35672797
[TBL] [Abstract][Full Text] [Related]
11. The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease.
Engelmann C; Tacke F
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054837
[TBL] [Abstract][Full Text] [Related]
12. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD.
Mashek DG
Mol Metab; 2021 Aug; 50():101115. PubMed ID: 33186758
[TBL] [Abstract][Full Text] [Related]
13. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.
Cimini FA; Barchetta I; Carotti S; Bertoccini L; Baroni MG; Vespasiani-Gentilucci U; Cavallo MG; Morini S
World J Gastroenterol; 2017 May; 23(19):3407-3417. PubMed ID: 28596677
[TBL] [Abstract][Full Text] [Related]
14. Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice.
Xia H; Zhu X; Zhang X; Jiang H; Li B; Wang Z; Li D; Jin Y
Biomed Pharmacother; 2019 Oct; 118():109287. PubMed ID: 31401392
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease.
Yin X; Guo X; Liu Z; Wang J
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769165
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (
Wu M; Lo TH; Li L; Sun J; Deng C; Chan KY; Li X; Yeh ST; Lee JTH; Lui PPY; Xu A; Wong CM
Elife; 2023 Aug; 12():. PubMed ID: 37580962
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
Li T; Huang X; Yue Z; Meng L; Hu Y
Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
Falkevall A; Mehlem A; Folestad E; Ning FC; Osorio-Conles Ó; Radmann R; de Hollanda A; Wright SD; Scotney P; Nash A; Eriksson U
J Hepatol; 2023 May; 78(5):901-913. PubMed ID: 36717026
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis.
Overi D; Carpino G; Franchitto A; Onori P; Gaudio E
Cells; 2020 Mar; 9(3):. PubMed ID: 32131439
[TBL] [Abstract][Full Text] [Related]
20. Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives.
Flessa CM; Kyrou I; Nasiri-Ansari N; Kaltsas G; Papavassiliou AG; Kassi E; Randeva HS
Curr Obes Rep; 2021 Jun; 10(2):134-161. PubMed ID: 33751456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
